Brief: Pacira Biosciences Announces Settlement Of U.S. Patent Litigation For Exparel
07/04/2025 21:43
April 7 (Reuters) - Pacira Biosciences Inc PCRX.O: PACIRA BIOSCIENCES ANNOUNCES SETTLEMENT OF U.S. PATENT LITIGATION FOR EXPAREL PACIRA BIOSCIENCES INC - FRESENIUS KABI LICENSED TO SELL GENERIC BUPIVACAINE IN U.S. FROM 2030 PACIRA BIOSCIENCES INC - FRESENIUS TO SELL GENERIC BUPIVACAINE WITHOUT LIMITATIONS FROM 2039 Source text: ID:nGNX71xX5B Further company coverage: PCRX.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Pacira BioSciences
See all newsUS STOCKS ON THE MOVE-Palantir, Haemonetics
U.S. STOCKS ON THE MOVE-Palantir, Haemonetics, Starbucks
Pacira BioSciences jumps on $1.65 billion Viatris buyout deal
Brief: Viatris - Pacira To Pay Viatris $62 Million Termination Fee Under Specified Circumstances
Pacira BioSciences jumps on $1.65 billion Viatris buyout deal